Home
Search
Search Results
Previously Searched
3135 results found
Expand All
Apply All
3135 results found

BIO Asia-Taiwan
Events  •  July 15, 2026
BIO Asia–Taiwan 2025 will showcase Taiwan's growing digital advantage in the biomed sector and highlight advances in biotech, pharmaceutical, medical devices, precision medicine, AI applications, ICT, IoT technologies, and new healthcare/medical investment opportunities.
Read More
BIO Asia-Taiwan

BIO International Convention
Agriculture & Environment, Human Health, BIO One-on-One Partnering  •  Events  •  June 22, 2026
The industry’s premier event hosts thousands from across the global biotech ecosystem. Four days of programming, networking, Company Presentations, and BIO Partnering™ focus on the future of our industry and make this a must-attend event.
Read More
BIO International Convention

BIO Investment & Growth Summit
Business Development, Human Health, Cost & Value of Biopharmaceuticals  •  Events  •  March 2, 2026
This premier conference brings together newly public and select private biotech companies with the investment banking community for two days of business and regulatory sessions, Company Presentations, BIO Partnering™ and networking.
Read More
BIO CEO & Investor Conference

Ride the Wave of Opportunity: Your BIO Partnering™ Guide for Meetings in Miami
Webinars  •  January 27, 2026
Get ready to take your business development strategy from the boardroom to the beach at the BIO Investment & Growth Summit, happening March 2–3, 2026, in sunny Miami Beach!Before you pack your sunglasses, join Mackensie Vernetti, BIO’s Vice President of Partnering, for a lively walkthrough of the BIO Partnering™ system—your essential tool for connecting with investors, innovators, and dealmakers who can take your company to the next level.In this session, you’ll learn how to:- Craft a standout partnering profile that catches attention- Search for and identify high-value partners and investors- Send targeted meeting requests that lead to real opportunities- Manage your schedule so you can focus on making deals and maybe catch a few rays)- Don’t miss this chance to ride the wave of opportunity and arrive in Miami ready to make the most of every meeting.
Read More
SD beach.jpg

BIO Partnering @JPM Week
Business Development, BIO One-on-One Partnering  •  Events  •  January 12, 2026
Maximize your investor outreach and business development activities during JPM week with BIO Partnering™. Find your next potential partner among the many users of our popular system, regardless of what events you’re attending during JPM week.
Read More
BIO Partnering @JPM Week

From JPM Week in SF to BIO in Miami: Partnering Skills for Any Weather
Webinars  •  December 8, 2025
Every year, JPM Healthcare Week sets the pace for biotech deal-making. But the skills and insights you gain from preparing for high stakes partnering meetings are valuable long after January. In this webinar, a panel of investors and biotech executives will share what makes a pitch stand out, common pitfalls to avoid and practical guidance you can use not just at JPM Week, but at events like the BIO Investment & Growth Summit (March 2-3, Miami Beach) and other partnering opportunities throughout the year.This webinar will feature:Strategies and tips for making the most of your time during JPM WeekMethods for improving your partnering meetingsHow to access the BIO and Novateur Ventures JPM Week Events Guide mobile appWhat to expect at the 2026 BIO Investment and Growth SummitLive Q&A with the speakers
Read More
Partnering in motion5

BIO's Comments on Advisory Committee on Immunization Practices (ACIP) - December 2025
Letters, Testimony & Comments  •  December 4, 2025
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in advance of the December 4-5, 2025 meeting. BIO encourages the reinstatement of several long-standing practices that have historically supported ACIP’s application of high-caliber science and transparent evidence-based decision making to safeguard Americans’ ability to protect against deadly infectious disease and avoid unintended disruptions to vaccine supply and patient access.BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 35 other nations. BIO membership includes vaccine developers and manufacturers who have worked closely with the public health community to support policies that help ensure access to innovation and life-saving vaccines for all individuals.For decades, the U.S. has been a global leader in scientific rigor and health innovation in vaccines, exemplified by policy developed through a transparent and predictable process. The Committee’s recommendations have earned trust because they have been consistently informed by structured evaluations that used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and the Evidence to Recommendation (EtR) processes. Continuous consistency and predictability in vaccine guidance from ACIP allows the U.S. to accelerate the delivery of vaccines to those wanting and needing them and to support the ongoing development of new vaccines.The longstanding ACIP process provides a model of integrity and transparency. Its success lies in structured reviews of the full body of evidence related to a vaccine conducted over multiple public meetings supported by…
Read More

Reauthorizing the PRV
Policy
prv

BIO Statement on the Retirement of Richard Pazdur from US FDA
Press Release  •  December 2, 2025
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career to public service and the needs of patients. He exemplifies the type of expert and steady leadership that has made the United States the home to the world’s leading medical breakthroughs. Dr. Pazdur’s departure raises serious concerns about the repeated turnover in key leadership occurring at the FDA.  We need organizational strength and stability at the Agency. This constant turmoil is undermining America's leadership in biotechnology, creating unprecedented regulatory instability and unpredictability, and risks ceding this critical sector to China. As BIO has long upheld - it is imperative that we retain and recruit scientific expertise and strong leadership of the highest caliber at our health agencies and that the standards that are the hallmark of these health institutions are upheld and advanced. We are at a tipping point. It is time to right this ship.”###About the Biotechnology Innovation Organization (BIO)BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
Read More

New Report Highlights State and Regional Strategies Powering U.S. Biotech
Press Release  •  December 2, 2025
WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report on best practices in bioscience economic development initiatives: The U.S. Bioscience Industry: A Powerful Engine for State Economies.The report details the diverse strategies states, cities, and municipalities are using to strengthen the bioscience ecosystem in their communities and support America's global leadership in biotechnology."This report underscores how deeply biotechnology is woven into our nation's fabric and serves as a roadmap for how states can help maintain America’s global biotechnology leadership," said John F. Crowley, President and CEO of BIO. "It shows how smart investments in biomanufacturing, research, and workforce development don't just bring effective medicines to patients, they also foster economic vitality across the country."The report examines public policy initiatives across all 50 states and Puerto Rico, highlights standout programs, and identifies national trends, including:R&D Incentives: Thirty-nine states and Puerto Rico now offer research and development tax credits, many refundable, to help early-stage bioscience companies access capital. Thirty-two states and Puerto Rico support SBIR/STTR matching grants for companies in their regions. In the coming decade, the bioscience market is expected to expand rapidly -- with forecasts predicting it will reach over $5 trillion by 2034.Jobs & Investment Boosts: States are expanding job creation and capital investment grants to attract and retain bioscience employers that inject our economy with good-paying jobs. In the U.S. alone, the bioscience industry's total economic impact (as measured by overall output) exceeded $3.2 trillion in 2023, supporting a large number of direct and indirect jobs.Manufacturing Tax Relief: Forty states and Puerto Rico are offering sales and use tax…
Read More